Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

The Associated Press June 21, 2010, 8:36AM ET

FDA grants approval for APP Pharmaceuticals drug

APP Pharmaceuticals received marketing approval for its generic anti-infective treatment, the company said Monday.

The Food and Drug Administration gave approval to market Aztreonam for Injection in two dosage strengths, 1 gram 20 milliliters and 2 grams 30 milliliters. APP plans to launch Aztreonam immediately.

It said Aztreonam is therapeutically equivalent to the Bristol-Myers Squibb Co. drug Azactam. The branded product had about $86 million in U.S. sales last year.

Aztreonam is intended to treat urinary tract, gynecologic and skin infections, and others.

APP Pharmaceuticals Inc. is a subsidiary of Fresenius Kabi Pharmaceuticals Holding Inc.

BW Mall - Sponsored Links

Buy a link now!